Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab

Multiple myeloma (MM) is incurable, so there is a significant unmet need for effective therapy for patients with relapsed or refractory disease. This situation has not changed despite the recent approval of the anti-CD38 antibody daratumumab, one of the most potent agents in MM treatment. The effici...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Leukemia 2021-01, Vol.35 (1), p.201-214
Hauptverfasser: García-Guerrero, Estefanía, Götz, Ralph, Doose, Sören, Sauer, Markus, Rodríguez-Gil, Alfonso, Nerreter, Thomas, Kortüm, K. Martin, Pérez-Simón, José A., Einsele, Hermann, Hudecek, Michael, Danhof, Sophia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!